XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Description of Business (Tables)
12 Months Ended
Jul. 31, 2024
Description of Business [Abstract]  
Schedule of Consolidated Financial Statements In addition to Rafael Holdings, Inc., the entities included in these consolidated financial statements are as follows:
Company  Country of Incorporation  Percentage Owned 
Broad Atlantic Associates, LLC  United States – Delaware   100%
IDT R.E. Holdings Ltd.  Israel   100%
Rafael Holdings Realty, Inc.  United States – Delaware   100%
Barer Institute, Inc.  United States – Delaware   100%*
Hillview Avenue Realty, JV  United States – Delaware   100%
Hillview Avenue Realty, LLC  United States – Delaware   100%
Rafael Medical Devices, LLC  United States – Delaware   68%
Levco Pharmaceuticals Ltd.  Israel   95%**
Farber Partners, LLC  United States – Delaware   93%
Pharma Holdings, LLC  United States – Delaware   90%***
LipoMedix Pharmaceuticals Ltd. (Note 9)  Israel   95%
Altira Capital & Consulting, LLC  United States – Delaware   67%
CS Pharma Holdings, LLC (Note 3)  United States – Delaware   45%***
Day Three Labs, Inc. (Note 10)  United States – Delaware   84%****
Cornerstone Pharmaceuticals, Inc. (Note 4)  United States – Delaware   67%
RP Finance, LLC (Note 5)  United States – Delaware   38%
*In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.
**During Fiscal 2022, the Company discontinued further material investment in Levco. In August 2023, Levco was dissolved.
***50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma Holdings, LLC and Pharma Holdings LLC, collectively own securities representing 67% of the outstanding capital stock of Cornerstone.
****In May 2024, the Company increased its ownership interest in Day Three Labs, Inc. from 79% to 84%.